Latest SEC Filings

SPAR Group, Inc.SPAR Group Reports 10.3% Revenue Decline and Net Loss in Q1 2026

ProMIS Neurosciences Inc.ProMIS Neurosciences Reports $8.2 Million Net Loss and Improved Cash Position in Latest Filing

Leatt CorpLeatt Corporation Reports 27% Revenue Growth to $19.51 Million in Q1 2026

NEUROONE MEDICAL TECHNOLOGIES CorpNeuroOne Reports 72% Revenue Growth in Q2 Fiscal 2026 Despite Net Loss

Adagio Medical Holdings, Inc.Adagio Medical Holdings Reports $6.995 Million Net Loss in Q1 2026, Focuses on Clinical Trials

PMV Pharmaceuticals, Inc.PMV Pharmaceuticals Reports $18M Net Loss in Q1 2026, Advances Clinical Trials for Rezatapopt

OptimumBank Holdings, Inc.OptimumBank Holdings Reports Significant Financial Growth with $1.27 Billion in Assets

Mereo BioPharma Group plcMereo BioPharma Reports $6.7 Million Net Loss in Q1 2026, Improved from Previous Year

Coya Therapeutics, Inc.Coya Therapeutics Reports Q1 2026 Financial Results with $7.2 Million Net Loss

Xilio Therapeutics, Inc.Xilio Therapeutics Reports $12.6M Revenue Growth and $9.5M Net Loss for Q1 2026

SAB Biotherapeutics, Inc.SAB Biotherapeutics Reports Increased Operating Expenses and Net Loss in Latest 10-Q Filing

Sagimet Biosciences Inc.Sagimet Biosciences Reports Q1 2026 Financial Results with Reduced Net Loss

Longduoduo Co LtdLongduoduo Company Limited Reports 64% Revenue Decline and Significant Net Loss in Latest Filing

ACHIEVE LIFE SCIENCES, INC.Achieve Life Sciences Reports $10.2 Million Net Loss in Q1 2026, Focuses on Cytisinicline Commercialization

Prelude Therapeutics IncPrelude Therapeutics Reports $4.58 Million Revenue in Q1 2026, Net Loss Improves to $10.39 Million

Sionna Therapeutics, Inc.Sionna Therapeutics Reports $26.8 Million Net Loss in Q1 2026, Increases Operating Expenses

Vestis CorpVestis Corporation Reports $659.4 Million Revenue with Net Income Turnaround in Latest Quarter

Olema Pharmaceuticals, Inc.Olema Pharmaceuticals Reports $53.1 Million Net Loss in Q1 2026, Increases R&D Spending

Ovid Therapeutics Inc.Ovid Therapeutics Reports Q1 2026 Financial Results with Increased Net Loss and No Revenue

C4 Therapeutics, Inc.C4 Therapeutics Reports Q1 2026 Financial Results with $6.2M Revenue and $25.1M Net Loss

Sleep Number CorpSleep Number Corporation Reports 19% Decline in Net Sales and $50.3 Million Loss in Q1 2026

Neuraxis, INCNeurAxis Reports 79.5% Revenue Growth to $1.6 Million in Latest Quarter

Passage BIO, Inc.Passage Bio Reports $7.6M Net Loss in Q1 2026, Announces Workforce Reduction

AMPCO PITTSBURGH CORPAmpco-Pittsburgh Reports 3.9% Net Sales Increase in Q1 2026, Net Loss of $0.9 Million

Unicycive Therapeutics, Inc.Unicycive Therapeutics Reports $12.8 Million Net Loss and Increased Cash Reserves for Q1 2026